Better Buy: Eli Lilly vs. Novo Nordisk. The Answer Is Becoming ...

6 days ago · Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for investors. Better Buy: Eli Lilly vs. Novo Nordisk. The …

CouponFollow Extension

77%
OFF

Better Buy: Novo Nordisk Vs. Eli Lilly | The Motley Fool

4 weeks from now

While Ozemipc is the brand name on everyone's lips when they talk about weight loss, it's only approved to control blood sugar and reduce the risk of heart attacks for patients with type 2 diabetes. Nevertheless, Ozempic sales soared 77% last year to $8.8 billion with help from off-labelweight-loss prescriptions as well as diabetes patients. Invest...

fool.com

32%
OFF

Better Buy: Eli Lilly Or Novo Nordisk? | The Motley Fool

4 weeks from now

Dec 23, 2024 · In this video, I will cover the recent updates regarding Novo Nordisk (NVO-0.32%) and whether or not the dip is worth buying over Eli Lilly (LLY-1.38%). Watch the short video to …

fool.com

13%
OFF

Lilly And Novo Went Head-to-Head Over Weight-Loss Drugs In …

4 weeks from now

Despite ever-increasing sales, Eli Lilly stock is down 13% in the fourth quarter, while Novo’s American depositary receipts, or ADRs, are down 28%. Over the year, the difference is more …

msn.com

38%
OFF

Eli Lilly Vs Novo Nordisk: A Recent Study Suggests This Company …

4 weeks from now

Aug 3, 2024 · Eli Lilly (LLY-1.38%) and Novo Nordisk (NVO-0.32%) are the two big names dominating the anti-obesity market today. They've been generating billions in revenue from …

fool.com

19%
OFF

Eli Lilly Vs. Novo Nordisk: What's The Better Weight-Loss Stock To …

4 weeks from now

Jul 27, 2023 · Two companies that are investing big money in weight-loss treatments are Eli Lilly (LLY-0.19%) and Novo Nordisk (NVO 0.32%). Shares of both companies are up more than …

fool.com

19%
OFF

Down 19% In 1 Day, Is Novo Nordisk Stock Still A Buy?

4 weeks from now

6 days ago · In contrast, per a different phase 3 study investigating a competing weight loss drug, Eli Lilly's (LLY-0.24%) Zepbound, patients treated with the highest dose lost 20.9% of their …

fool.com

FAQs about Better Buy: Eli Lilly vs. Novo Nordisk. The Answer Is Becoming ... Coupon?

Should you buy Eli Lilly vs Novo Nordisk?

Eli Lilly vs Novo Nordisk: A Recent Study Suggests This Company Has the Best Weight Loss Drug was originally published by The Motley Fool These healthcare stocks are up more than 400% in the past five years, thanks to their dominance in the anti-obesity market. ...

Is Eli Lilly a good stock to buy right now?

This recent news, while promising, doesn't necessarily make Eli Lilly a better stock to buy right now. Both of these stocks are good long-term investments. Shares of Novo Nordisk trade at 44 times trailing earnings, versus more than 110 times earnings for Eli Lilly, which makes Novo Nordisk stock a more attractive investment right now. ...

Is Lilly a good investment over Novo Nordisk?

I see Lilly as the superior investment over Novo Nordisk -- and frankly, I don't think it's even close. While I see the recent declines in Novo stock as a prime example of overblown panic selling, Lilly's progress against Wegovy -- combined with its diverse and growing medical portfolio -- make the company hard to pass up. ...

Are Eli Lilly & Novo Nordisk the best anti-obesity companies?

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are the two big names dominating the anti-obesity market today. They've been generating billions in revenue from their treatments, and there's still a lot of growth for these companies. ...

Should you buy Novo Nordisk to take advantage of soaring weight-management sales?

Before buying Novo Nordisk stock to take advantage of soaring weight-management sales, you should know that Eli Lilly (LLY -3.68%) has a weight-management program too. Some analysts think Mounjaro, a diabetes treatment from Eli Lilly, could become an even bigger weight-management drug than Novo Nordisk's. ...

Will Eli Lilly & Novo Nordisk diverge in 2024?

The future market for GLP-1s is almost certainly enormous, and will benefit those with weight-loss drugs on the market. But it’s unlikely to be all smooth sailing, and the divergence of Eli Lilly and Novo Nordisk in 2024, and in the fourth quarter in particular, is a clear sign of that. ...